EU/3/06/377

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in November 2006 on request of the sponsor.

On 20 June 2006, orphan designation (EU/3/06/377) was granted by the European Commission to Insmed Europe Ltd., United Kingdom, for mecasermin rinfabate for the treatment of patients with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

Key facts

Active substance
Mecasermin rinfabate
Disease / condition
Treatment of growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH
Date of first decision
20/06/2006
Outcome
Withdrawn
EU designation number
EU/3/06/377

Sponsor's contact details

Insmed Europe Ltd.
Compass House
Vision Park
Chivers Way
Histon
Cambridge CB4 9AD,
United Kingdom
Telephone: +44 01 223 257 743
Telefax: +44 01 223 257 800
E-mail: information@insmed.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating